Directors Holdings

RNS Number : 4459V

Allergy Therapeutics PLC

10 July 2009

 



Friday 10 July 2009

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Directors Holdings 

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that, further to an announcement dated 6 July 2009, the 12,500,000 ordinary shares issued to Azure Ventures Limited, pursuant to a partial exercise of a warrant on 2 July 2009 have been admitted to trading on AIM. 

Azure Ventures Limited is now interested in 116,666,666 shares, representing 42.19 per cent. of the Company's total voting rights.

Alejandro Weinstein, a non-executive director of the Company, is one of the ultimate beneficiaries under The Karjiang Pharma Trust which is the sole shareholder of Azure Ventures Limited. 

The Company's issued share capital consists of 276,498,551 ordinary shares. 

For further information

Allergy Therapeutics	[phone]
Keith Carter, Chief Executive
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw
Financial Dynamics	[phone]
Ben Brewerton/ Susan Quigley

 

END

 

 

MSCUUUBPMUPBPUB